GLUT1 and ASCT2 Protein Expression in Papillary Thyroid Carcinoma Patients and Relation to Hepatitis C Virus: A Propensity-Score Matched Analysis

References

• Yan KL, Li S, Tseng C-H, et al. Rising incidence and incidence-based mortality of thyroid cancer in California, 2000-2017. J Clin Endocrinol Metab. 2020;105(6):356. doi:10.1210/clinem/dgaa121
   Web of Science ®Google Scholar
• Rossi ED, Pantanowitz L, Hornick JL. A worldwide journey of thyroid cancer incidence centred on tumour histology. Lancet Diabetes Endocrinol. 2021;9(4):193–194.
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569–580.
   PubMed Web of Science ®Google Scholar
• Schmidbauer B, Menhart K, Hellwig D, Grosse J. Differentiated Thyroid Cancer-Treatment: state of the Art. Int J Mol Sci. 2017;18(6):46.
   Web of Science ®Google Scholar
• Ciavardelli D, Bellomo M, Consalvo A, Crescimanno C, Vella V. Metabolic Alterations of Thyroid Cancer as Potential Therapeutic Targets. Biomed Res Int. 2017;2017:2545031.
   PubMed Web of Science ®Google Scholar
• Adekola K, Rosen ST, Shanmugam M. Glucose transporters in cancer metabolism. Curr Opin Oncol. 2012;24(6):650–654.
   PubMed Web of Science ®Google Scholar
• Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 2009;121(1):29–40.
   PubMed Web of Science ®Google Scholar
• Kedia-Mehta N, Finlay DK. Competition for nutrients and its role in controlling immune responses. Nat Commun. 2019;10(1):2123.
   PubMed Web of Science ®Google Scholar
• Cazzaniga M, Bonanni B. Relationship Between Metabolic Reprogramming and Mitochondrial Activity in Cancer Cells. Understanding The Anticancer Effect of Metformin and Its Clinical Implications. Anticancer Res. 2015;35(11):5789.
   PubMed Web of Science ®Google Scholar
• Sun HW, Yu XJ, Wu WC, et al. GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma. PLoS One. 2016;11(12):e0168907.
   PubMed Web of Science ®Google Scholar
• Wang J, Ye C, Chen C, et al. Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(10):16875–16886.
   PubMedGoogle Scholar
• Mamun AA, Hayashi H, Yamamura A, Nayeem MJ, Sato M. Hypoxia induces the translocation of glucose transporter 1 to the plasma membrane in vascular endothelial cells. J Physiol Sci. 2020;70(1):44.
   PubMed Web of Science ®Google Scholar
• Matsuzu K, Segade F, Matsuzu U, Carter A, Bowden DW, Perrier ND. Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid. 2004;14(10):806–812.
   PubMed Web of Science ®Google Scholar
• Chandan VS, Faquin WC, Wilbur DC, Khurana KK. The role of immunolocalization of CD57 and GLUT-1 in cell blocks in fine-needle aspiration diagnosis of papillary thyroid carcinoma. Cancer. 2006;108(5):331–336.
   PubMed Web of Science ®Google Scholar
• Carvalho KC, Cunha IW, Rocha RM, et al. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics. 2011;66(6):965–972.
   PubMed Web of Science ®Google Scholar
• Jóźwiak P, Lipińska A. The role of glucose transporter 1 (GLUT1) in the diagnosis and therapy of tumors. Postepy Hig Med Dosw. 2012;66:165–174.
   Web of Science ®Google Scholar
• Morani F, Pagano L, Prodam F, Aimaretti G, Isidoro C. Loss of expression of the oncosuppressor PTEN in thyroid incidentalomas associates with GLUT1 plasma membrane expression. Panminerva Med. 2012;54(2):59–63.
   PubMed Web of Science ®Google Scholar
• Morani F, Phadngam S, Follo C, et al. PTEN regulates plasma membrane expression of glucose transporter 1 and glucose uptake in thyroid cancer cells. J Mol Endocrinol. 2014;53(2):247–258.
   PubMed Web of Science ®Google Scholar
• Zhang B, Xie Z, Li B. The clinicopathologic impacts and prognostic significance of GLUT1 expression in patients with lung cancer: a meta-analysis. Gene. 2019;689:76–83.
   PubMed Web of Science ®Google Scholar
• Khabaz MN, Qureshi IA, Al-Maghrabi JA. GLUT 1 expression is a supportive mean in predicting prognosis and survival estimates of endometrial carcinoma. Ginekol Pol. 2019;90(10):582–588.
   PubMed Web of Science ®Google Scholar
• Yang H, Zhong JT, Zhou SH, Han HM. Roles of GLUT-1 and HK-II expression in the biological behavior of head and neck cancer. Oncotarget. 2019;10(32):3066–3083.
   PubMedGoogle Scholar
• Kaida H, Hiromatsu Y, Kurata S, et al. Relationship between clinicopathological factors and fluorine-18-fluorodeoxyglucose uptake in patients with papillary thyroid cancer. Nucl Med Commun. 2011;32(8):690–698.
   PubMed Web of Science ®Google Scholar
• Wang YF, Liu B, Fan XS, et al. Thyroid carcinoma showing thymus-like elements: a clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis. Am J Clin Pathol. 2015;143(2):223–233.
   PubMed Web of Science ®Google Scholar
• Scalise M, Pochini L, Console L, Losso MA, Indiveri C. The Human SLC1A5 (ASCT2) Amino Acid Transporter: from Function to Structure and Role in Cell Biology. Front Cell Dev Biol. 2018;6:96.
   PubMed Web of Science ®Google Scholar
• Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine Metabolism in Cancer: understanding the Heterogeneity. Trends Cancer. 2017;3(3):169–180.
   PubMed Web of Science ®Google Scholar
• Kim HM, Lee YK, Koo JS. Expression of glutamine metabolism-related proteins in thyroid cancer. Oncotarget. 2016;7(33):53628–53641.
   PubMedGoogle Scholar
• Lopes C, Pereira C, Medeiros R. ASCT2 and LAT1 Contribution to the Hallmarks of Cancer: from a Molecular Perspective to Clinical Translation. Cancers. 2021;13(2):21.
   Web of Science ®Google Scholar
• Wen SS, Zhang TT, Xue DX, et al. Metabolic reprogramming and its clinical application in thyroid cancer. Oncol Lett. 2019;18(2):1579–1584.
   PubMed Web of Science ®Google Scholar
• Wang H, Ma Z, Cheng X, Tuo B, Liu X, Li T. Physiological and Pathophysiological Roles of Ion Transporter-Mediated Metabolism in the Thyroid Gland and in Thyroid Cancer. Onco Targets Ther. 2020;13:12427–12441.
   PubMed Web of Science ®Google Scholar
• Enomoto K, Hotomi M. Amino Acid Transporters as Potential Therapeutic Targets in Thyroid Cancer. Endocrinol Metab. 2020;35(2):227–236.
   Web of Science ®Google Scholar
• Montella M, Crispo A, Pezzullo L, et al. Is hepatitis C virus infection associated with thyroid cancer? A case-control study. Int J Cancer. 2000;87(4):611–612.
   PubMed Web of Science ®Google Scholar
• Montella M, Pezzullo L, Crispo A, et al. Risk of thyroid cancer and high prevalence of hepatitis C virus. (- 1):- 133. Int J Med. 2019;1:543
   Google Scholar
• Fallahi P, Ferrari SM, Politti U, Giuggioli D, Ferri C, Antonelli A. Autoimmune and neoplastic thyroid diseases associated with hepatitis C chronic infection. Int J Endocrinol. 2014;2014:935131.
   PubMed Web of Science ®Google Scholar
• Wang P, Jing Z, Liu C, et al. Hepatitis C virus infection and risk of thyroid cancer: a systematic review and meta-analysis. Arab J Gastroenterol. 2017;18(1):1–5.
   PubMed Web of Science ®Google Scholar
• Fallahi P, Ferrari SM, Giuggioli D, et al. Thyroid involvement in hepatitis C - associated mixed cryoglobulinemia. Hormones. 2014;13(1):16–23.
   PubMedGoogle Scholar
• Montella M, Pezzullo L, Crispo A, et al. Risk of thyroid cancer and high prevalence of hepatitis C virus. Oncol Rep. 2003;10(1):133–136.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Fallahi P, et al. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid. 2007;17(5):447–451.
   PubMed Web of Science ®Google Scholar
• Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol. 2010;172(9):1092–1097.
   PubMed Web of Science ®Google Scholar
• Yan S, Coffing BN, Li Z, et al. Diagnostic and Prognostic Value of ProEx C and GLUT1 in Melanocytic Lesions. Anticancer Res. 2016;36(6):2871–2880.
   PubMed Web of Science ®Google Scholar
• Toda K, Nishikawa G, Iwamoto M, et al. Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer. Int J Mol Sci. 2017;18(8):498.
   PubMed Web of Science ®Google Scholar
• Ratajczak M, Gaweł D, Godlewska M. Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update. Int J Mol Sci. 2021;22:21.
   Web of Science ®Google Scholar
• Zambrano A, Molt M, Uribe E, Salas M. Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy. Int J Mol Sci. 2019;20:13.
   Web of Science ®Google Scholar
• Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Sheu SY. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med. 2012;37(2):121–127.
   PubMed Web of Science ®Google Scholar
• Pereira KM, Chaves FN, Viana TS, et al. Oxygen metabolism in oral cancer: HIF and GLUTs (Review). Oncol Lett. 2013;6(2):311–316.
   PubMed Web of Science ®Google Scholar
• Burrows N, Resch J, Cowen RL, et al. Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas. Endocr Relat Cancer. 2010;17(1):61–72.
   PubMed Web of Science ®Google Scholar
• Jiwa LS, van Diest PJ, Hoefnagel LD, et al. Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases. BMC Cancer. 2014;14:864.
   PubMed Web of Science ®Google Scholar
• Zuo J, Wen J, Lei M, et al. Hypoxia promotes the invasion and metastasis of laryngeal cancer cells via EMT. Med Oncol. 2016;33(2):15.
   PubMed Web of Science ®Google Scholar
• Kim S, Jung WH, Koo JS. The expression of glutamine-metabolism-related proteins in breast phyllodes tumors. Tumour Biol. 2013;34(5):2683–2689.
   PubMedGoogle Scholar
• Kim BH, Lee CH, Kim SJ, et al. Clinicopathologic characteristics of synchronous primary thyroid cancer detected by initial staging 18F-FDG PET-CT examination in patients with underlying malignancy. Thyroid. 2013;23(11):1431–1436.
   PubMed Web of Science ®Google Scholar
• Montella M, Crispo A, de Bellis G, et al. HCV and cancer: a case-control study in a high-endemic area. Liver. 2001;21(5):335–341.
   PubMedGoogle Scholar
• Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206(4):469–477.
   PubMed Web of Science ®Google Scholar
• Kasai D, Adachi T, Deng L, et al. HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters. J Hepatol. 2009;50(5):883–894.
   PubMed Web of Science ®Google Scholar